WVE
Wave Life Sciences, Inc. Health Care Pharmaceutical Preparations Russell 3000
$3.59Close
$3.09 – $21.3152-week range
Late-januaryNext report · estimated
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 2 · weaker than 98% of stocks over 12 months
- Far from its high 83% below its 52-week high
- Distribution down-day volume 1.9× up-day volume over 50 sessions
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
83%
1wk
up 12.9%
price change
1mo
down 3.0%
price change
12-month return
down 57%
market up 11% ·
its own down 67%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
down 61%
year on year
EPS growth
—
latest quarter
Sales growth
up 73%
latest quarter · +147 pts
ROE
down 56%
return on equity
Free cash margin
down 440%
-$188.2M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.2%
$0.22 a day · 2×ATR $3.14
RS
2 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
0.54
50 sessions
Implied move
—
no scheduled report
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Revenue shrinking Revenue fell 60.5% over the year, from $108.3M to $42.7M.
Last reported
Oct 27, 2026
Last shock
Aug 11, 2026-17% in one session2.3× volumeno filing matched-29% since
Financials
- Net -478%
- Free cash -440%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $20.1M | $41.0M | $3.6M | $113.3M | $108.3M | $42.7M |
| Operating income | -$153.4M | -$127.0M | -$162.7M | -$68.0M | -$110.4M | -$215.4M |
| Net income | -$149.9M | -$122.2M | -$161.8M | -$57.5M | -$97.0M | -$204.4M |
| Net margin | -747% | -298% | -4434% | -51% | -90% | -478% |
| Earnings per share | — | -$2.36 | -$2.05 | -$0.54 | -$0.70 | -$1.21 |
| Free cash flow | -$117.3M | -$89.6M | -$129.1M | -$20.5M | -$152.0M | -$188.2M |
| Free cash margin | -584% | -219% | -3539% | -18% | -140% | -440% |
| Cash | $184.5M | $150.6M | $88.5M | $200.4M | $302.1M | $602.1M |
| Shareholders' equity | $82.8M | $32.5M | -$45.1M | $39.6M | $209.5M | $518.4M |
| Shares outstanding | 48.78m | 59.84m | 86.92m | 119.16m | 153.04m | 0 |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 27, 2026 | Quarterly ↗ | Sep 30, 2026 | 27d |
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| Apr 28, 2026 | Quarterly ↗ | Mar 31, 2026 | 28d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Jul 30, 2025 | Quarterly ↗ | Jun 30, 2025 | 30d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 4, 2025 | Annual ↗ | Dec 31, 2024 | 63d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 10, 2024 | Quarterly ↗ | Mar 31, 2024 | 40d |
| Mar 6, 2024 | Annual ↗ | Dec 31, 2023 | 66d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 27, 2026 | Results ↗ |
| Jul 30, 2026 | Results · Regulation FD ↗ |
| Jun 26, 2026 | Shareholder vote ↗ |
| May 18, 2026 | Regulation FD · Other events ↗ |
| Apr 28, 2026 | Results · Regulation FD ↗ |
| Apr 21, 2026 | Other events ↗ |
| Apr 15, 2026 | Material agreement · Other events ↗ |
| Mar 26, 2026 | Regulation FD · Other events ↗ |
| Feb 26, 2026 | Results · Regulation FD ↗ |
| Feb 2, 2026 | Other events ↗ |
| Jan 12, 2026 | Results · Regulation FD ↗ |
| Dec 11, 2025 | Material agreement · Regulation FD · Other events ↗ |